Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) received accelerated FDA approval for Lynozyfic on July 2, 2025, a significant development for treating relapsed or refractory multiple myeloma. JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron with a $800 price target, citing potential easing of recent headwinds. The company’s strength lies in its Dupixent product, which is expected to drive growth. With a strong balance sheet and growing contributions from Dupixent, there is room for upside in Regeneron shares. This news underscores Regeneron’s position as a key player in the biotechnology industry.

Read more at Yahoo Finance: Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target